A nationally-published, award-winning journalist, Alex Biese joined the CURE team as an assistant managing editor in April 2023. Prior to that, Alex's work was published in outlets including the Chicago Sun-Times, MTV.com, USA TODAY and the Press of Atlantic City. Alex is a member of NLGJA: The Association of LGBTQ+ Journalists, and also performs at the Jersey Shore with the acoustic jam band Somewhat Relative.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Read More
Remeron Increases Energy Consumption in NSCLC and Anorexia
February 3rd 2024For patients with advanced non-small cell lung cancer and anorexia, the use of the antidepressant Remeron has been shown to increase energy consumption, as researchers look for therapies to answer an issue faced by many patients.
Read More
Patients With Cervical Cancer Survivor Can Thrive With Social Support
January 31st 2024“When you have support, you have answers to some of your unknowns and that can provide stability and ease in anxiety and depression, and truly propel you into thriving,” a cervical cancer survivor and advocate tells CURE®.
Read More
No Increased Blood-Related Side Effects With Radium-223 in Prostate Cancer
January 27th 2024Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.
Read More
Max Hypofractionated Concurrent Chemoradiation Dose Identified in NSCLC
January 25th 2024Researchers claim to have determined the maximum=tolerated dose and usage of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy boost for patients with locally advanced unresectable non-small cell lung cancer, according to recently published findings.
Read More
Hepatitis Treatments Underutilized Among ‘Sickest’ With Liver Cancer
January 19th 2024Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even among patients who undergo curative surgery.
Read More
Patients With COVID-19 Treated for Cancer at Risk for Thromboembolisms
January 18th 2024Patients recently treated for cancer who required hospitalization for COVID-19 were at risk for venous thromboembolisms (VTEs), recent research has found, with investigators determining that patients who experience a thromboembolic event (TEE) are at a 20% to 25% risk of death.
Read More
Endocrine Therapy Effective Subsequent Advanced Breast Cancer Treatment
January 16th 2024Endocrine therapy, particularly when administered in combination with Verzenio (abemaciclib), is effective when compared with chemotherapy among patients with metastatic breast cancer who experienced disease progression on Ibrance (palbociclib), according to recently published research.
Read More
Enrollment Continues in Study Evaluating ONCT-534 For Advanced Prostate Cancer
January 11th 2024Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).
Read More